Tag: depression
Magnus highlights new SAINT clinical data at 2024 NYC Neuromodulation Conference
Magnus Medical has announced promising new clinical data on its Stanford accelerated intelligent neuromodulation therapy (SAINT) at the 2024 NYC Neuromodulation Conference (31 July–4...
MagVenture and Magnus to collaborate on bringing SAINT neuromodulation system to...
MagVenture has announced a partnership with Magnus Medical that is intended to provide its industry-leading MagPro magnetic stimulation system to support an “exciting new chapter”...
UK study indicates post-stroke depression may be more common and long-lasting...
Researchers have argued that “more needs to be done” for depressed stroke survivors in light of new findings showing that almost 60% of stroke...
Flow announces pivotal trial results indicating tDCS headset is twice as...
Flow Neuroscience, the creator of the Flow transcranial direct current stimulation (tDCS) headset for at-home, non-invasive brain stimulation to treat depression, has announced the...
Interim analysis of MOOD trial produces positive neuromodulation data in depression...
Neurolief has announced positive results from a planned interim analysis of the ongoing, randomised controlled MOOD pivotal trial, which is studying Relivion DP—a novel...
Revascularisation capable of improving mood in depressed patients with carotid atherosclerosis
A prospective study has demonstrated that carotid intervention can improve mood in depressed patients with advanced carotid disease, in addition to enabling cognitive improvements...
RECOVER trial will provide “thorough understanding” of VNS response in depression...
A new randomised controlled trial (RCT)—the “largest ever” of its kind in the major depressive disorder (MDD) space—will attempt to provide a “thorough understanding”...
Magnus shares study results indicating SAINT depression treatment changes abnormal brain...
Magnus Medical has shared promising results from a clinical trial published in the Proceedings of the National Academy of Sciences indicating that treatment with SAINT neuromodulation...
Magnus receives US FDA clearance for SAINT neuromodulation system in severe...
Magnus Medical has announced receipt of 510(k) clearance from the US Food and Drug Administration (FDA) for its SAINT neuromodulation system for the treatment of...
Ybrain receives Translational Research Award for tDCS technology
Ybrain recently received the Translational Research Award at this year's Neuroergonomics and NYC Neuromodulation Conferences (28 July–1 August, New York City, USA) for its transcranial direct...
FDA approves launch of “largest clinical trial to date” for tDCS...
Flow Neuroscience, which claims to be the creator of Europe’s first medically approved brain stimulation device to treat depression at home, has received full...
Single-patient study offers promise for individualised depression treatment with DBS
Despite its small sample size, a study in which a patient received closed-loop, deep brain stimulation (DBS) therapy has demonstrated positive clinical outcomes and...
Novel neuromodulation technique could be “gamechanger” in treatment-resistant depression
Stanford accelerated intelligent neuromodulation therapy (SAINT)—a novel, high-dose intermittent theta-burst stimulation (iTBS)—was found to be safe and more effective than sham stimulation in a...
Research shows brain rhythm changes occur ‘within minutes’ of DBS surgery...
New research published in Translational Psychiatry presents evidence that brief intraoperative exposure to therapeutic deep brain stimulation (DBS) at the time of implantation surgery induces...
Return to work and depressive symptoms in young stroke survivors
Matthias Volz (University of Kassel, Kassel, Germany), Simon Ladwig and Katja Werheid (both Humboldt-Universität zu Berlin, Berlin, Germany) discuss the burden of post-stroke depression...
Magnus Medical announces Breakthrough Device designation for novel depression treatment and...
Magnus Medical has announced that the US Food and Drug Administration (FDA) has granted the company Breakthrough Device designation for its individualised, rapid-acting, non-invasive...
Flow Neuroscience receives Series A funding to advance tDCS depression treatment
Flow Neuroscience, the creator of what is currently Europe’s only medically approved transcranial direct current stimulation (tDCS) device and behavioural therapy app for depression,...
How stimulation is changing the future of mental health treatment
Daniel Månsson (Flow Neuroscience, Malmö, Sweden) outlines the benefits held by transcranial direct-current stimulation (tDCS) in the treatment of depression—and how clinical evidence supporting...
New study shows significant positive impact of vagus nerve stimulation therapy...
Adding vagus nerve stimulation (VNS) therapy to treatment as usual has been demonstrated to improve outcomes in patients with treatment-resistant bipolar depression (TRBD). In...
Soterix wins IDE for depression treatment trial
Soterix Medical has announced that it received US Food and Drug Administration (FDA) investigational device exemption (IDE) to launch a trial of its non-invasive transcranial...
New study shows significant positive impact of vagus nerve stimulation therapy...
Adding vagus nerve stimulation (VNS) therapy to treatment as usual (TAU) has been demonstrated to improve outcomes in patients with treatment-resistant bipolar depression (TRBD)....
LivaNova collaborates with Verily to fuel research into vagus nerve stimulation...
LivaNova has announced a research collaboration with Verily, an Alphabet company, to capture measures of depression within its RECOVER clinical study, which is evaluating...
LivaNova enrols first patient in RECOVER clinical study
LivaNova has announced the first patient enrolled in their RECOVER trial, a prospective, multi-centre, randomised controlled blinded trial demonstrating the safety and effectiveness of...
The burden of a stroke call: 56% of US neurointerventionalists meet...
Fifty-six per cent of US neurointerventionalists meet criteria for burnout. This statistic, presented by Kyle Fargen from Wake Forest Baptist Health in Winston-Salem (USA)...
Medication-free treatment for depression launches in the UK
Flow launches a medication-free treatment for depression comprising a brain stimulation headset and therapy app. In Europe, Flow is classified as a Class IIa...
CMS trial clearance for LivaNova’s vagus nerve stimulation therapy for treatment-resistant...
LivaNova has recognised that the US Centers for Medicare & Medicaid Services (CMS) finalised its National Coverage Determination (NCD) for the LivaNova vagus nerve...
Largest ever study of depression and anxiety to transform mental health...
Researchers at King’s College London are launching the largest ever single study of depression and anxiety. By recruiting at least 40,000 people in England...
The truth about physician burnout
Writing in the Journal of NeuroInterventional Surgery, Kyle M Fargen (Wake Forest University, Winston-Salem, USA) and Joshua A Hirsch (Massachusetts General Hospital, Boston, USA)...
